ADAA Conference

^{Learn something new, network, and be surprised...}

 

Intracranial Approaches to Characterizing and Treating Depression

Kelly Bijanki, PhD

Interventional Psychiatry: The Time is Now

Nolan Williams, MD

Translational Brain Circuit Engineering to Treat Mood & Anxiety Disorders

Alik Widge, MD, PHD

Affirmative Mental Health Care for Transgender and Gender Diverse Youth: A Clinical Guide

Aron Janssen, MD

Ketamine and Psychedelics - Where are we now?

Sanjay Mathew, MD

Sanjay J. Mathew, M.D. is the Marjorie Bintliff Johnson and Raleigh White Johnson, Jr. Vice Chair for Research and Professor in the Menninger Department of Psychiatry & Behavioral Sciences at Baylor College of Medicine. He is also a staff psychiatrist at the Michael E. Debakey VA Medical Center (MEDVAMC) in Houston, Texas. He graduated from Dartmouth College and Baylor College of Medicine, and trained in psychiatry at Columbia University and the New York State Psychiatric Institute, where he also completed a NIH-funded research fellowship in affective and anxiety disorders. Dr. Mathew began his faculty career at the Icahn School of Medicine at Mount Sinai where he co-founded and directed the Mood & Anxiety Disorders Program. In 2010, Dr. Mathew was recruited back to his hometown of Houston to direct Baylor’s Mood & Anxiety Disorders Program. His research program focuses on developing novel therapies for patients with treatment-resistant mood and anxiety disorders and PTSD, with a particular focus on rapid-acting glutamate-modulating agents. 

Dr. Mathew’s research program has been funded by NIMH, Department of Veterans Affairs, Patient-Centered Outcomes Research Institute (PCORI), and industry in the areas of experimental therapeutics and pathophysiology of treatment-resistant depression, suicide, and PTSD. He has authored or co-authored over 130 manuscripts and book chapters, and serves on the editorial board of several journals. In addition to his long involvement with ADAA including serving as Chair of the Program Committee (2017-2018), Dr. Mathew is a member of the American College of Neuropsychopharmacology, and board member of the American Society of Clinical Psychopharmacology. An active clinician and teacher, Dr. Mathew has been selected by his peers as a “Best Doctor” every year since 2011, and has received awards for his teaching of psychopharmacology.

Next-Generation Strategies to Refine and Optimize DBS for Depression.  

Helen Mayberg, MD

Deep Brain Stimulation is an experimental treatment for intractable depression. The availability of implanted sensing systems combined with precise image-guided targeting and new machine learning analytic strategies provide new tools for treatment optimization and mechanistic perspectives on the trajectory and sustainability of DBS effects.  Further use of computer vision to assess naturalistic face and body movements offers new opportunities to link first-person experiences to brain and behavioral biomarkers that can reliably monitor and guide DBS management.

Helen Mayberg, MD is Professor of Neurology, Neurosurgery, Psychiatry and Neuroscience, and the Mount Sinai Professor in Neurotherapeutics at the Icahn School of Medicine where she serves as founding Director of the Nash Family Center for Advanced Circuit Therapeutics. Dr. Mayberg trained in Neurology at Columbia's Neurological Institute in New York, followed by a research fellowship in nuclear medicine at Johns Hopkins. She is a member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and the National Academy of Inventors among other honors. Over her career, she and her colleagues have characterized neural systems mediating major depression and its recovery, defined imaging-based illness subtypes to optimize treatment selection and introduced the first use of deep brain stimulation for treatment resistant patients.  

Unmet Needs in the Treatment of Depression

Charles B. Nemeroff, MD, PhD

Charles B. Nemeroff is currently the Professor and Chair, Department of Psychiatry and Director, Institute for Early Life Adversity Research. Previously, Dr. Nemeroff was the Leonard M. Miller Professor and Chairman of the Department of Psychiatry and Behavioral Sciences, and Clinical Director of the Center on Aging at the University of Miami Miller School of Medicine.  He is past president of the American College of Psychiatrists and the American College of Neuropsychopharmacology.  His research has focused on the neurobiology of mood and anxiety disorders with a focus on the long term consequences of child abuse and neglect and how these changes increase vulnerability for psychiatric disorders in adulthood.  He has published more than 1000 research reports and reviews, and 15 books.  He is a member of the Institute of Medicine of the National Academy of Sciences (USA). The 2022 Edition of Research.com Ranking of Top 1000 Scientists in the field of Medicine ranked Dr. Nemeroff #228 in the world and #153 in the United States.

Dr. Nemeroff has been an ADAA member since 1999, was elected ADAA Chief Medical Officer in March, 2019 and is currently Board President.

Accelerated Theta Burst TMS in the Management of Treatment Resistant Depression

Nolan Williams, MD